Healthcare provider profile · identity verified

Eric C Last, DO

Internal Medicine · WANTAGH, NY · NPI 1528097367

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	923	265
Amlodipine Besylate	Amlodipine Besylate	541	149
Levothyroxine Sodium	Levothyroxine Sodium	357	93
Rosuvastatin Calcium	Rosuvastatin Calcium	298	90
Alprazolam	Alprazolam	241	45
Losartan Potassium	Losartan Potassium	225	58
Metoprolol Succinate	Metoprolol Succinate	202	57
Escitalopram Oxalate	Escitalopram Oxalate	198	56
Metformin Hcl Er	Metformin Hcl	198	55
Potassium Chloride	Potassium Chloride	172	51
Synthroid	Levothyroxine Sodium	165	43
Hydrochlorothiazide	Hydrochlorothiazide	155	39
Omeprazole	Omeprazole	149	43
Pantoprazole Sodium	Pantoprazole Sodium	148	44
Fluticasone Propionate	Fluticasone Propionate	136	63
Chlorthalidone	Chlorthalidone	135	33
Gabapentin	Gabapentin	133	41
Trulicity	Dulaglutide	123	21
Simvastatin	Simvastatin	122	32
Ezetimibe	Ezetimibe	102	29
Ramipril	Ramipril	96	27
Jardiance	Empagliflozin	95	24
Tamsulosin Hcl	Tamsulosin Hcl	95	24
Allopurinol	Allopurinol	94	26
Eliquis	Apixaban	87	26
Famotidine	Famotidine	85	29
Zolpidem Tartrate	Zolpidem Tartrate	82	14
Metoprolol Tartrate	Metoprolol Tartrate	80	23
Furosemide	Furosemide	78	18
Olmesartan Medoxomil	Olmesartan Medoxomil	77	25
Sertraline Hcl	Sertraline Hcl	76	20
Carvedilol	Carvedilol	74	23
Citalopram Hbr	Citalopram Hydrobromide	71	19
Alendronate Sodium	Alendronate Sodium	68	23
Lisinopril	Lisinopril	67	22
Albuterol Sulfate Hfa	Albuterol Sulfate	66	20
Duloxetine Hcl	Duloxetine Hcl	66	16
Clopidogrel	Clopidogrel Bisulfate	64	20
Pravastatin Sodium	Pravastatin Sodium	57	19
Montelukast Sodium	Montelukast Sodium	55	17
Risedronate Sodium	Risedronate Sodium	53	17
Torsemide	Torsemide	50	18
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	45	12
Benazepril Hcl	Benazepril Hcl	45	12
Meloxicam	Meloxicam	45	suppressed
Atenolol	Atenolol	43	12
Cefuroxime	Cefuroxime Axetil	42	37
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	41	suppressed
Enalapril Maleate	Enalapril Maleate	40	12
Mounjaro	Tirzepatide	39	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	38	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	37	suppressed
Lorazepam	Lorazepam	37	12
Trazodone Hcl	Trazodone Hcl	36	15
Azelastine Hcl	Azelastine Hcl	33	13
Janumet	Sitagliptin Phos/Metformin Hcl	33	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	32	26
Glimepiride	Glimepiride	32	11
Clonazepam	Clonazepam	30	suppressed
Breo Ellipta	Fluticasone/Vilanterol	28	suppressed
Fosinopril Sodium	Fosinopril Sodium	27	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	27	suppressed
Metformin Hcl	Metformin Hcl	25	suppressed
Klor-Con M20	Potassium Chloride	23	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	23	23
Nebivolol Hcl	Nebivolol Hcl	22	suppressed
Prolia	Denosumab	22	12
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Tramadol Hcl	Tramadol Hcl	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	15
Finasteride	Finasteride	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Ozempic	Semaglutide	19	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Symbicort	Budesonide/Formoterol Fumarate	18	suppressed
Bupropion Xl	Bupropion Hcl	17	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Valsartan	Valsartan	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Klayesta	Nystatin	15	11
Lovastatin	Lovastatin	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Cefadroxil	Cefadroxil	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Lipitor	Atorvastatin Calcium	13	suppressed
Nadolol	Nadolol	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	12	suppressed
Clarinex	Desloratadine	12	suppressed
Levetiracetam Er	Levetiracetam	12	suppressed
Nexium	Esomeprazole Magnesium	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	11
Nystatin	Nystatin	12	suppressed
Prednisone	Prednisone	12	11
Donepezil Hcl	Donepezil Hcl	11	suppressed
Erythromycin	Erythromycin Base	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Jentadueto	Linagliptin/Metformin Hcl	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error